Delivery Order SPE2DB22D2007-SPE2DB25FJ5KH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $17,437.44. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, represents a non-set-aside competitive procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $6,888.58. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) with a ceiling value of $33,129.47. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and carries no set-aside designation, indicating it was competitively awarded. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a $31,936.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global...
- The Defense Logistics Agency awarded a delivery order valued at $4,100.96 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on August 22, 2025, with completion due by August 25, 2025. This firm fixed price, non-competitive delivery order was issued under a larger indefinite delivery contract vehicle and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the Department of Defense medical supply chain. The...
- The Defense Logistics Agency awarded a $28,730.55 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for RINVOQ ER 45 mg tablets (28-count units) with a ceiling value of $74,205.29. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made competitively without set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $29,343.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 26, 2025, with an ultimate completion date of September 29, 2025. This competitively awarded, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5KHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 45 mg tablets (28-count unit of use packaging) with a ceiling value of $156,487.67. This firm fixed-price delivery order, which is expected to be completed by September 29, 2025, was competitively awarded without a set-aside designation. AmerisourceBergen will perform the contract at its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and healthcare solutions provider. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive IDC serves as the prime contract vehicle enabling AmerisourceBergen to supply pharmaceutical products and medical supplies to support military healthcare programs globally, including serving the Defense Health Agency and U.S. Coast Guard. RINVOQ ER (upadacitinib extended-release) is a targeted immunosuppressant used in treating rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of specialty pharmaceuticals included within the DLA's medical supply chain procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $156.5k | 9/26/25 |